Solutions
Real Endpoints brings a wide range of strategic and operational market access solutions to our clients.
Insights
Real Endpoints is a thought leader within the pharmaceutical industry. We actively publish and lead panels and are frequently quoted in the press.
Our Solutions
News and Events
High Priced Drugs for Rare Disease: Leading US Payers Discuss Cost Concerns, Value-Based Contracts and ICER
by Cathy Kelly
Expert perspectives on reimbursement for high-cost therapies, both chronic and curative, were discussd at the recent Biotechnology Innovation Organization virtual international convention. The panel discussion, moderated by Real Endpoints CEO Jeff Berkowitz, focused on pharmacy benefit manager and payer concerns with affordability, the role of patient advocacy, value-based purchasing, and ICER value assessments
Rare Disease Therapies are No Longer Rare: Can the US Healthcare Reimbursement System Handle Chronic Treatments for Orphan Diseases
Moderator: Jeffrey Berkowitz, CEO and Director
Real Endpoints
Real Endpoints is excited to be moderating this important panel on reimbursement of chronic rare and orphan disease therapies at the upcoming BIO International Digital Convention
June 8, 2020
-
June 12, 2020
What Your Board Needs to Know About Market Access and Oncology: A Webinar for Top Management
Panelist: Jeffrey Berkowitz, CEO and Director
Roger Longman, Founder and Chairman
Real Endpoints
CELLO Health BioConsulting Webinar with Real Endpoints: In this senior executive webinar, we’ll give a boardroom presentation, and take your questions, on cancer’s unique payer situation and its stability — or instability. Our focus: how the informed biotech executive team manages early (and late) clinical and commercial development to ensure success not just with the FDA but in what may be a very different and less favorable reimbursement environment
May 19, 2020
12:00pm ET
Don’t Waste this Crisis: Solving the Patient Cost-Share Problem
by Jeff Berkowitz
Insurers have been playing a beneficial role in the pandemic crises by expanding access to, and cutting patient costs of, Covid-related diagnosis and treatment. How might insurer’s apply the COVID-19 cost-share initiatives to other population-wide problems?
Recent Insights
view archive >
June 30, 2020
Opportunity Offered by a Good Crisis: COVID-19 IMPACT ON INNOVATIVE PRICING MODELS
An interview with Roger Longman, Cofounder and Chairman of Real Endpoints LLC in which he discusses innovative and value-based contracting models currently in use and reflects on the downstream effects of innovative pricing on patients and their out-of-pocket costs.
read full interview >
April 20, 2020
Drug Coverage in the Pandemic: US Payers Shift Focus From Costs To Access, For Now
US payers are concentrating on ensuring access to health care during the COVID-19 pandemic, which has led them to relax, postpone or waive some formulary and coverage policies to avoid disruptions in patient access to prescription drugs.
read full insights article >National Business Director
Top 5 Pharma
Senior Director
Specialty Access Solutions, Top 5 Pharma
Director of Operations
Reimbursement and Patient Support Services, Top 20 Pharma
Chronis H. Manolis, RPh
Vice President, Pharmacy UPMC Health Plan
Jack Bailey
President , GlaxoSmithKline U.S.